Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
June 09, 2016

From eligibility to CDx: developing and implementing effective biomarker strategies for Immuno-oncology trials

Presented at Biomarkers World Congress and Diagnostics on May 18, 2016 this presentation highlights the challenges Immuno-oncology trials face. Scientists from Q2 Solutions discuss how they have engaged Pharma and focused critical tools—anatomic pathology, flow cytometry, and genomics—to address these challenges, as well as how this knowledge was leveraged to facilitate transitioning to companion diagnostic development.

Patrice Hugo, Ph.D., Chief Scientific Officer
Patrick Hurban, Ph.D., Senior Director and Global Head, Genomic Development/Esoteric Assays
The Power of the Central Laboratory for Immuno-Oncology Drug Development

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Read More